Blood-Brain Barrier Breakdown in Acute and Chronic Cerebrovascular Disease

被引:611
作者
Yang, Yi [1 ]
Rosenberg, Gary A. [1 ,2 ,3 ]
机构
[1] Univ New Mexico, Dept Neurol, Hlth Sci Ctr, Albuquerque, NM 87107 USA
[2] Univ New Mexico, Dept Neurosci, Hlth Sci Ctr, Albuquerque, NM 87107 USA
[3] Univ New Mexico, Dept Cell Biol & Physiol, Hlth Sci Ctr, Albuquerque, NM 87107 USA
关键词
blood-brain barrier; brain ischemia; endothelium; ischemia; matrix proteins; neuroprotection; vascular cognitive impairment; white matter disease; FOCAL CEREBRAL-ISCHEMIA; TISSUE-PLASMINOGEN ACTIVATOR; WHITE-MATTER LESIONS; MATRIX-METALLOPROTEINASE INHIBITORS; INTRACEREBRAL HEMORRHAGE; VASCULAR DEMENTIA; STROKE; DISRUPTION; PERICYTES; MATRIX-METALLOPROTEINASE-9;
D O I
10.1161/STROKEAHA.110.608257
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Disruptions of the blood-brain barrier (BBB) and edema formation both play key roles in the development of neurological dysfunction in acute and chronic cerebral ischemia. Animal studies have revealed the molecular cascades that are initiated with hypoxia/ischemia in the cells forming the neurovascular unit and that contribute to cell death. Matrix metalloproteinases cause reversible degradation of tight junction proteins early after the onset of ischemia, and a delayed secondary opening during a neuroinflammatory response occurring from 24 to 72 hours after. Cyclooxygenases are important in the delayed opening as the neuroinflammatory response progresses. An early opening of the BBB within the 3-hour therapeutic window for tissue-type plasminogen activator can allow it to enter the brain and increase the risk of hemorrhage. Chronic hypoxic hypoperfusion opens the BBB, which contributes to the cognitive changes seen with lacunar strokes and white matter injury in subcortical ischemic vascular disease. This review will describe the molecular and cellular events associated with BBB disruption and potential therapies directed toward restoring the integrity of the neurovascular unit. (Stroke. 2011; 42:3323-3328.)
引用
收藏
页码:3323 / 3328
页数:6
相关论文
共 43 条
[1]   Blood-brain barrier dysfunction in Binswanger's disease; an immunohistochemical study [J].
Akiguchi, I ;
Tomimoto, H ;
Suenaga, T ;
Wakita, H ;
Budka, H .
ACTA NEUROPATHOLOGICA, 1998, 95 (01) :78-84
[2]   Pericytes Control Key Neurovascular Functions and Neuronal Phenotype in the Adult Brain and during Brain Aging [J].
Bell, Robert D. ;
Winkler, Ethan A. ;
Sagare, Abhay P. ;
Singh, Itender ;
LaRue, Barb ;
Deane, Rashid ;
Zlokovic, Berislav V. .
NEURON, 2010, 68 (03) :409-427
[3]   Early hemorrhage growth in patients with intracerebral hemorrhage [J].
Brott, T ;
Broderick, J ;
Kothari, R ;
Barsan, W ;
Tomsick, T ;
Sauerbeck, L ;
Spilker, J ;
Duldner, J ;
Khoury, J .
STROKE, 1997, 28 (01) :1-5
[4]   DIVERSE ROLES OF MATRIX METALLOPROTEINASES AND TISSUE INHIBITORS OF METALLOPROTEINASES IN NEUROINFLAMMATION AND CEREBRAL ISCHEMIA [J].
Candelario-Jalil, E. ;
Yang, Y. ;
Rosenberg, G. A. .
NEUROSCIENCE, 2009, 158 (03) :983-994
[5]   Post-ischaemic treatment with the cyclooxygenase-2 inhibitor nimesulide reduces blood-brain barrier disruption and leukocyte infiltration following transient focal cerebral ischaemia in rats [J].
Candelario-Jalil, Eduardo ;
Gonzalez-Falcon, Armando ;
Garcia-Cabrera, Michel ;
Leon, Olga Sonia ;
Fiebich, Bernd L. .
JOURNAL OF NEUROCHEMISTRY, 2007, 100 (04) :1108-1120
[6]   Cancer therapy - Matrix metalloproteinase inhibitors and cancer: Trials and tribulations [J].
Coussens, LM ;
Fingleton, B ;
Matrisian, LM .
SCIENCE, 2002, 295 (5564) :2387-2392
[7]   Pericytes are required for blood-brain barrier integrity during embryogenesis [J].
Daneman, Richard ;
Zhou, Lu ;
Kebede, Amanuel A. ;
Barres, Ben A. .
NATURE, 2010, 468 (7323) :562-U238
[8]   Periventricular cerebral white matter lesions predict rate of cognitive decline [J].
de Groot, JC ;
de Leeuw, FE ;
Oudkerk, M ;
van Gijn, J ;
Hofman, A ;
Jolles, J ;
Breteler, MMB .
ANNALS OF NEUROLOGY, 2002, 52 (03) :335-341
[9]  
DEREUCK J, 1980, NEUROLOGY, V30, P920
[10]   Pericytes: Pluripotent cells of the blood brain barrier [J].
Dore-Duffy, Paula .
CURRENT PHARMACEUTICAL DESIGN, 2008, 14 (16) :1581-1593